MX2020008359A - Uso de ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico y ácido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxílico en el tratamiento del tinnitus, pérdida de audición neurosensorial aguda, enfermedad de meniere, síndrome de tourette, trastorno por déficit de atención e hiperactividad y adicción. - Google Patents

Uso de ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico y ácido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxílico en el tratamiento del tinnitus, pérdida de audición neurosensorial aguda, enfermedad de meniere, síndrome de tourette, trastorno por déficit de atención e hiperactividad y adicción.

Info

Publication number
MX2020008359A
MX2020008359A MX2020008359A MX2020008359A MX2020008359A MX 2020008359 A MX2020008359 A MX 2020008359A MX 2020008359 A MX2020008359 A MX 2020008359A MX 2020008359 A MX2020008359 A MX 2020008359A MX 2020008359 A MX2020008359 A MX 2020008359A
Authority
MX
Mexico
Prior art keywords
amino
carboxylic acid
difluoromethyliden
meniere
addiction
Prior art date
Application number
MX2020008359A
Other languages
English (en)
Inventor
Matthew During
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of MX2020008359A publication Critical patent/MX2020008359A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporcionan métodos para tratar el tinnitus, la pérdida de audición neurosensorial aguda, la enfermedad de Meniere, el síndrome de Tourette, el ADHD o la adicción con ácido (1S,3S)-3-amino-4- (difluorometiliden) ciclopentano-1-carboxílico o una sal farmacéuticamente aceptable de este. Se proporcionan métodos para tratar el tinnitus, la pérdida de audición neurosensorial aguda, la enfermedad de Meniere, el síndrome de Tourette, el ADHD o la adicción con ácido (S)-3-amino-4-(difluorom etilenil) ciclopent-1-eno-1-carboxílico. También se proporcionan composiciones terapéuticas que pueden usarse para mejorar uno o más síntomas del tinnitus, la pérdida de audición neurosensorial aguda, la enfermedad de Meniere, el síndrome de Tourette, el ADHD o la adicción.
MX2020008359A 2018-02-08 2019-02-08 Uso de ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico y ácido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxílico en el tratamiento del tinnitus, pérdida de audición neurosensorial aguda, enfermedad de meniere, síndrome de tourette, trastorno por déficit de atención e hiperactividad y adicción. MX2020008359A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862628020P 2018-02-08 2018-02-08
US201862628541P 2018-02-09 2018-02-09
PCT/US2019/017201 WO2019157273A1 (en) 2018-02-08 2019-02-08 Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere's disease, tourette's syndrome, attention deficit hyperactivity disorder and addiction

Publications (1)

Publication Number Publication Date
MX2020008359A true MX2020008359A (es) 2020-11-24

Family

ID=67475310

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008359A MX2020008359A (es) 2018-02-08 2019-02-08 Uso de ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico y ácido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxílico en el tratamiento del tinnitus, pérdida de audición neurosensorial aguda, enfermedad de meniere, síndrome de tourette, trastorno por déficit de atención e hiperactividad y adicción.

Country Status (10)

Country Link
US (1) US10653652B2 (es)
EP (1) EP3735237A4 (es)
JP (1) JP2021512920A (es)
KR (3) KR20250167147A (es)
CN (1) CN112261938A (es)
AU (1) AU2019216742B2 (es)
CA (1) CA3090258A1 (es)
IL (1) IL276287A (es)
MX (1) MX2020008359A (es)
WO (1) WO2019157273A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016342027B2 (en) 2015-10-23 2021-05-13 Navitor Pharmaceuticals, Inc. Modulators of Sestrin-GATOR2 interaction and uses thereof
TWI776886B (zh) 2017-04-26 2022-09-11 美商奈維特製藥公司 Sestrin-gator2交互作用之調節劑及其用途
US11771671B2 (en) 2018-02-08 2023-10-03 Ovid Therapeutics Inc. Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction
US20190298674A1 (en) * 2018-03-29 2019-10-03 Ovid Therapeutics, Inc. Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders
JP7644002B2 (ja) 2018-10-24 2025-03-11 ナビター ファーマシューティカルズ， インコーポレイテッド 多形化合物およびその使用
EP4051259A4 (en) 2019-11-01 2023-11-22 Navitor Pharmaceuticals, Inc. METHOD OF TREATMENT USING A MMOC1 MODULATOR

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794413B1 (en) * 2002-07-19 2004-09-21 Northwestern University Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase
US6656172B1 (en) * 2002-09-27 2003-12-02 Medtronic, Inc. Method for treating severe tinnitus
US20070179168A1 (en) * 2005-11-28 2007-08-02 Orexigen Therapeutics, Inc. Methods of treating anxiety disorders
WO2011106692A2 (en) 2010-02-25 2011-09-01 Northwestern University Methods of using (1s, 3s) -3-amino-4-difluoromethylenyl-1-cyclopentanoic acid
EP2621475A1 (en) 2010-10-02 2013-08-07 Link Research&Grants Corporation Treatment of tinnitus and related auditory dysfunctions
WO2013006857A1 (en) 2011-07-07 2013-01-10 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism
WO2013087090A1 (en) 2011-12-12 2013-06-20 Auris Medical Ag Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system
CA2862816A1 (en) * 2012-01-27 2013-08-01 Catalyst Pharmaceutical Partners Method of treating tourette's disorder with gaba-aminotransferase inactivators
BR112018007026B1 (pt) * 2015-10-09 2022-06-21 Northwestern University Composto, composição farmacêutica, e usos do composto
IL310065A (en) 2017-02-08 2024-03-01 Ovid Therapeutics Inc Methods for treating seizure disorders and Prader-Willi syndrome

Also Published As

Publication number Publication date
EP3735237A1 (en) 2020-11-11
KR20240154700A (ko) 2024-10-25
JP2021512920A (ja) 2021-05-20
IL276287A (en) 2020-09-30
EP3735237A4 (en) 2021-03-17
CA3090258A1 (en) 2019-08-15
KR20250167147A (ko) 2025-11-28
AU2019216742A1 (en) 2020-08-13
AU2019216742B2 (en) 2024-05-09
CN112261938A (zh) 2021-01-22
KR20210007948A (ko) 2021-01-20
US10653652B2 (en) 2020-05-19
WO2019157273A1 (en) 2019-08-15
US20190240174A1 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
MX2019009190A (es) Uso de gaboxadol en el tratamiento de tinnitus.
CL2020000122A1 (es) Métodos de tratamiento para la fibrosis quística.
DOP2019000241A (es) ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
DOP2017000271A (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
DOP2017000272A (es) Métodos de diagnóstico para tratamiento con linfocitos t
MX2022000143A (es) Metodos novedosos.
UY35313A (es) Antiadhesion de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3
SV2017005489A (es) Terapias de combinación para el tratamiento de cánceres
MX383932B (es) Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue.
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
CL2018000811A1 (es) Formulaciones de aminoácidos de liberación modificada administradas por vía oral.
MX2022003128A (es) Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular.
ECSP21031200A (es) Uso de reboxetina para el tratamiento de narcolepsia
IL276287A (en) Use of (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopentane-1-ene-1-carboxylic acid in the treatment of buzzing, Sensorineural hearing loss, Meniere's disease, Tourette's syndrome, ADHD and addiction
CO2018005983A2 (es) Compuestos de isoindol
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
MX394475B (es) Métodos para el tratamiento de las condiciones relacionadas con la inflamación utilizando moduladores antiinflamatorios y metábolicos pluripotentes.
MY179105A (en) Methods of treating alzheimer's disease
MX2020009999A (es) Composiciones farmacéuticas para inhibir citocinas inflamatorias.
CL2019001918A1 (es) Métodos para tratar infecciones bacterianas.
MX2018002816A (es) Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t.
MX2021003606A (es) Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv.
MX2021011598A (es) Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.
MX2018013943A (es) Metodo de tratamiento de hiperglucemia.